How to stop the silent pandemic AMR was discussed by 500 experts from 13 countries at the 7th AMR Conference in Basel. At that time, in Brussels, there were two proposals on the table on how to compensate novel resistance-breaking antimicrobials, from which one got the green light in the new pharma legislation.
Smarter, faster, cheaper: Veeva shows how
Latest NewsThis year’s Veeva R&D and Quality Summit in Madrid, accentuated the current trends and needs of the pharma and life sciences industries.
Santhera licences vamorolone rights to Catalyst Pharmaceuticals
Latest NewsSanthera Pharmaceuticals Holding has exclusively granted the rights to commercialise its Duchenne muscular dystrophy drug vamorolone in North America to Catalyst Pharmaceuticals Inc.
BioSenic halts ALLOB development
Latest NewsBioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB.
Neogap fully takes over TCER Oncology shares
Latest NewsSwedish personalised immunotherapy specialist Neogap Therapeutics AB has acquired the remaining shares of its subsidiary, TCER Oncology AB through two new shareholders.
Antibody provides broad protection vs hantaviruses
Latest NewsAn international research team headed by Pablo Guardado-Calvo at Institut Pasteur Paris has demonstrated evaluated antibody efficacy against lethal hantaviruses.
New headquarter in Krakow
BackgroundThe new Krakow headquarters of preclinical CRO Selvita have opened.
3P Biopharmaceuticals lands in the United States.
BackgroundProgress in the fight against AMR
BackgroundHow to stop the silent pandemic AMR was discussed by 500 experts from 13 countries at the 7th AMR Conference in Basel. At that time, in Brussels, there were two proposals on the table on how to compensate novel resistance-breaking antimicrobials, from which one got the green light in the new pharma legislation.
Syncona launches new gene therapy company Beacon Therapeutics
Latest NewsSyncona Ltd had spun-out the ophtalmology specialist Beacon Therapeutics Holdings Ltd with a £96m Series A financing.
Roche to file MAA for eculizumab competitor
Latest NewsRoche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.